Linnea Cipriano is a partner in Goodwin's Intellectual Property Litigation practice, specializing in patent litigation in federal courts and the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB).
Linnea’s federal court practice focuses on clients in the life science industry, representing both plaintiffs and defendants in high stakes patent litigations. Linnea’s experience includes technologies across the life science industry, including biotechnology, cell and gene therapies, small and large molecule pharmaceuticals, nutritional supplements, chemical manufacturing, medical devices, and drug delivery technologies.
Linnea also co-leads Goodwin’s post-grant proceedings practice and was shortlisted for LMG Life Sciences Post Grant Proceedings Attorney of the Year in 2024. At the PTAB, she has successfully represented petitioners and patent owners in a diverse spectrum of industries, encompassing pharmaceuticals, cell therapies, electronic devices, manufacturing methods, and medical devices.
Linnea blends her scientific background with her legal expertise to serve her clients with unparalleled dedication and insight.
Representative Matters
- Consulting clients in tech and life science industries regarding strategy for filing and defending against PTAB challenges
- Counseling clients regarding freedom to operate in the materials science industry
- Assisting biosimilar manufacturers navigate the “patent dance” according to the BPCIA
- In re Lumify, (D.N.J.): Representing Dr. Reddy’s Laboratories in litigation related to the product Lumify, including defeating a preliminary injunction motion
- Tecan Genomics, Inc. v. Invitae Corp; Tecan Genomics, Inc. v. Qiagen Sciences, LLC (D.Del.): Representing Tecan Genomics in patent litigation related to DNA sequencing technology
- Tris Pharma, Inc. v. Teva Pharmaceuticals (D.N.J.): Representing Teva in Hatch-Waxman litigation related to a generic version of a drug product for the treatment of ADHD
- Par Pharmaceutical, Inc., et al. v. Amneal Pharmaceuticals of New York, LLC, et al. (D. Del.): Representing Amneal in a patent infringement case related to a generic drug product for the treatment of hypotension
- Representing Celltrion at the PTAB and in patent infringement litigations related to Celltrion’s rituximab and trastuzumab biosimilars
- Slayback Pharma LLC/Dr. Reddy’s Laboratories S.A. v. Eye Therapies, LLC (IPR2022-00142 and -00146; IPR2024-00467 and -00563): Lead counsel for petitioner in four IPRs related to eye drop formulations
- Kelonia Therapeutics, Inc. v. Interius Biotherapeutics, Inc. (PGR20024-00008): Representing Interius Biotherapeutics in defending a PGR challenge of its patent related to its cell therapy technology
- Fusion Pharmaceuticals v. Universitat Heidelberg (IPR2023-00551): Representing Fusion Pharmaceuticals in an IPR challenge of a patent related to radiopharmaceuticals
- Glux Visual Effects Tech (Shenzhen) Co. et al. v. Ultravision Technologies, LLC (IPR2020-01049, -01050, and -01052): Lead Counsel for Petitioners in three IPRs successfully challenging patents related to digital displays
- Fresenius Kabi USA, LLC v. Novo Nordisk A/S (IPR2022-00657): Lead counsel for petitioner challenging patents related to peptide formulations
- Representing the ACLU and individuals seeking access to COVID treatment while in the custody of ICE
- Representing American Bird Conservancy in a case brought under the federal Environmental Protection Act against New York State Department of Parks, Recreation, and Historic Preservation regarding protection of Piping Plovers in Jones Beach State Park
- Representing individuals applying for political asylum in the U.S.
- Representing unaccompanied minors in family court and in petitions to USCIS
Professional Experience
Prior to joining Goodwin, Linnea was an associate in the New York office of Kenyon & Kenyon. She also worked as a legal intern at Cleveland Clinic Innovations and as a research technologist at the Cleveland Clinic Foundation.
Linnea served on the Board of NYIPLA 2022-2024 and currently serves as co-chair of the NYIPLA Women in IP Law Committee. She is also a member of the PTAB Bar Association and the ChIPs Network.
Credentials
Education
JD2010
Case Western Reserve University
MSPharmacology2007
Case Western Reserve University
BSBiochemistry2004
Catholic University of America
Admissions
Bars
- New York
- U.S. Patent and Trademark Office (USPTO)
Courts
- U.S. District Court for the Southern District of New York
- U.S. Court of Appeals for the Federal Circuit
Recognition & Awards
- LMG Life Sciences Post Grant Proceedings Attorney of the Year Shortlist (2024)
- IAM Patent 1000 (2022, 2023, 2024)
- Super Lawyers (2015-2021)
- The Legal 500 (2021)
Publications
- Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S. 2023-2024 ed.,” published by Thomson Reuters, January 2024
- Co-Author, “Key PTAB Priorities And changes Under Vidal,” Law 360, June 2023
- Co-Author, “3 Best Practices For Patent Claims Against Secret Methods,” Law360, August 12, 2019
- Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.,” published by Thomson Reuters, November 2019
Linnea is the managing editor of the Goodwin PTAB Trial Tracker periodic newsletter.